Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98)

Morie Gertz, Montserrat Rue, Emily Blood, Lynne S. Kaminer, David H. Vesole, Philip R. Greipp

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

Waldenström macroglobulinemia (WM) is a low-grade lymphoplasmacytic lymphoma that strongly expresses CD20 on the cell surface. This study was undertaken to determine the response rate of patients with untreated or previously treated WM to the monoclonal antibody rituximab, which is directed against CD20+ expressed by B-cell lymphomas. Thirty-four untreated and thirty-five previously treated patients received rituximab 375 mg/m2 weekly for 4 consecutive weeks by intravenous infusion on days 1, 8, 15, and 22. Sixty-nine patients were evaluable for response; 19 (27.5%) achieved an objective response and 17 (24.6%) achieved a minor response. The overall response rate was 52.2% (90% CI [41.6%, 62.6%]). Of previously untreated patients 35.3% vs. 20% of previously treated patients achieved an objective response. Median response duration was not significantly different between previously untreated (27 months) and previously treated patients (not reached, P = 0.8). Rituximab produced objective or minor responses in 52.2% of patients and is an active agent in the treatment of WM. Grade 4 toxicity was seen in 11%.

Original languageEnglish (US)
Pages (from-to)2047-2055
Number of pages9
JournalLeukemia and Lymphoma
Volume45
Issue number10
DOIs
StatePublished - Oct 1 2004

Fingerprint

Waldenstrom Macroglobulinemia
B-Cell Lymphoma
Rituximab
Intravenous Infusions
Non-Hodgkin's Lymphoma
Monoclonal Antibodies

Keywords

  • Lymphoplasmacytic lymphoma
  • Monoclonal IgM protein
  • Rituximab
  • Waldenström macroglobulinemia

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM) : An Eastern Cooperative Oncology Group Study (E3A98). / Gertz, Morie; Rue, Montserrat; Blood, Emily; Kaminer, Lynne S.; Vesole, David H.; Greipp, Philip R.

In: Leukemia and Lymphoma, Vol. 45, No. 10, 01.10.2004, p. 2047-2055.

Research output: Contribution to journalArticle

Gertz, Morie ; Rue, Montserrat ; Blood, Emily ; Kaminer, Lynne S. ; Vesole, David H. ; Greipp, Philip R. / Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM) : An Eastern Cooperative Oncology Group Study (E3A98). In: Leukemia and Lymphoma. 2004 ; Vol. 45, No. 10. pp. 2047-2055.
@article{91a83094f7b14daf8dd3a3ec2a184ffd,
title = "Multicenter phase 2 trial of rituximab for Waldenstr{\"o}m macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98)",
abstract = "Waldenstr{\"o}m macroglobulinemia (WM) is a low-grade lymphoplasmacytic lymphoma that strongly expresses CD20 on the cell surface. This study was undertaken to determine the response rate of patients with untreated or previously treated WM to the monoclonal antibody rituximab, which is directed against CD20+ expressed by B-cell lymphomas. Thirty-four untreated and thirty-five previously treated patients received rituximab 375 mg/m2 weekly for 4 consecutive weeks by intravenous infusion on days 1, 8, 15, and 22. Sixty-nine patients were evaluable for response; 19 (27.5{\%}) achieved an objective response and 17 (24.6{\%}) achieved a minor response. The overall response rate was 52.2{\%} (90{\%} CI [41.6{\%}, 62.6{\%}]). Of previously untreated patients 35.3{\%} vs. 20{\%} of previously treated patients achieved an objective response. Median response duration was not significantly different between previously untreated (27 months) and previously treated patients (not reached, P = 0.8). Rituximab produced objective or minor responses in 52.2{\%} of patients and is an active agent in the treatment of WM. Grade 4 toxicity was seen in 11{\%}.",
keywords = "Lymphoplasmacytic lymphoma, Monoclonal IgM protein, Rituximab, Waldenstr{\"o}m macroglobulinemia",
author = "Morie Gertz and Montserrat Rue and Emily Blood and Kaminer, {Lynne S.} and Vesole, {David H.} and Greipp, {Philip R.}",
year = "2004",
month = "10",
day = "1",
doi = "10.1080/10428190410001714043",
language = "English (US)",
volume = "45",
pages = "2047--2055",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "10",

}

TY - JOUR

T1 - Multicenter phase 2 trial of rituximab for Waldenström macroglobulinemia (WM)

T2 - An Eastern Cooperative Oncology Group Study (E3A98)

AU - Gertz, Morie

AU - Rue, Montserrat

AU - Blood, Emily

AU - Kaminer, Lynne S.

AU - Vesole, David H.

AU - Greipp, Philip R.

PY - 2004/10/1

Y1 - 2004/10/1

N2 - Waldenström macroglobulinemia (WM) is a low-grade lymphoplasmacytic lymphoma that strongly expresses CD20 on the cell surface. This study was undertaken to determine the response rate of patients with untreated or previously treated WM to the monoclonal antibody rituximab, which is directed against CD20+ expressed by B-cell lymphomas. Thirty-four untreated and thirty-five previously treated patients received rituximab 375 mg/m2 weekly for 4 consecutive weeks by intravenous infusion on days 1, 8, 15, and 22. Sixty-nine patients were evaluable for response; 19 (27.5%) achieved an objective response and 17 (24.6%) achieved a minor response. The overall response rate was 52.2% (90% CI [41.6%, 62.6%]). Of previously untreated patients 35.3% vs. 20% of previously treated patients achieved an objective response. Median response duration was not significantly different between previously untreated (27 months) and previously treated patients (not reached, P = 0.8). Rituximab produced objective or minor responses in 52.2% of patients and is an active agent in the treatment of WM. Grade 4 toxicity was seen in 11%.

AB - Waldenström macroglobulinemia (WM) is a low-grade lymphoplasmacytic lymphoma that strongly expresses CD20 on the cell surface. This study was undertaken to determine the response rate of patients with untreated or previously treated WM to the monoclonal antibody rituximab, which is directed against CD20+ expressed by B-cell lymphomas. Thirty-four untreated and thirty-five previously treated patients received rituximab 375 mg/m2 weekly for 4 consecutive weeks by intravenous infusion on days 1, 8, 15, and 22. Sixty-nine patients were evaluable for response; 19 (27.5%) achieved an objective response and 17 (24.6%) achieved a minor response. The overall response rate was 52.2% (90% CI [41.6%, 62.6%]). Of previously untreated patients 35.3% vs. 20% of previously treated patients achieved an objective response. Median response duration was not significantly different between previously untreated (27 months) and previously treated patients (not reached, P = 0.8). Rituximab produced objective or minor responses in 52.2% of patients and is an active agent in the treatment of WM. Grade 4 toxicity was seen in 11%.

KW - Lymphoplasmacytic lymphoma

KW - Monoclonal IgM protein

KW - Rituximab

KW - Waldenström macroglobulinemia

UR - http://www.scopus.com/inward/record.url?scp=4544309546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544309546&partnerID=8YFLogxK

U2 - 10.1080/10428190410001714043

DO - 10.1080/10428190410001714043

M3 - Article

C2 - 15370249

AN - SCOPUS:4544309546

VL - 45

SP - 2047

EP - 2055

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 10

ER -